While targeting the BTICs with the CD133 antibody for the site-specific delivery of nanocage cargo, holding an extremophilic sulphated polysaccharide (SPS)-based novel prodrug complex is reported for the first time in the paper as a novel strategy in cancer combinatorial therapy. The gene discussed is PROM1; the disease is cancer.